In untreated patients, a mean final height ranging from 151 cm to 155 cm (59.5 inches to 61 inches) has been reported. Treatment with gonadotropin-releasing hormone (GnRH) agonists improves the final height of children with rapidly progressing puberty, based on a calculation of a predicted final height, particularly in younger children (less than 6 years old).     There is only minimally convincing evidence of an improvement in final height in girls 6 to 8 years old; and in those between 8 and 10 years old, GnRH agonists have shown no benefit in final height.  There are few results of final height benefit in boys. Gonadotropin secretion recommences approximately 3 to 4 months after stoppage of treatment, with normal pubertal progress and fertility.
In some patients, short- and long-term psychological consequences can be more profound than the loss in height potential. This can lead to disruptive behavior, difficulties in interpersonal relationships, and an earlier onset of sexual behavior. Practical difficulties with respect to menarche in very young girls can also lead to psychosocial adjustment.
All patients need to be monitored during treatment to ensure that puberty is halted. Response to therapy can be assessed clinically by symptoms,  the growth velocity, bone age, pubertal progression, measurement of serum gonadotropins and/or sex steroid measurement, or serial ultrasound scans. 
Growth should be monitored on age- and sex-appropriate growth charts to ensue that the adolescent achieves full growth potential. Continued pubertal assessment is best assessed by Tanner staging.   Testicular size is documented as a measurement of the longest axis or by the testicular volume using the Prader orchidometer. Image 4 Image 5
Monitoring of patients with an underlying etiology (e.g., intracranial tumors, McCune-Albright syndrome) will depend upon the individual condition.
Treatment should be stopped once an acceptable age of puberty is reached. Gonadotropin secretion recommences approximately 3 to 4 months after stoppage of treatment, with normal pubertal progress and fertility.
Girls should be told to report the onset of any breakthrough bleeding while on treatment. Patient information is available from the National Institute of Health. http://www.nichd.nih.gov/health/topics/puberty/Pages/default.aspx [NIH: puberty and precocious puberty]